Similar articles

• Use of the activated partial thromboplastin time for heparin monitoring.

  Smythe MA, Koerber JM, Westley SJ, Nowak SN, Begle RL, Balasubramaniam M, Mattson JC. Smythe MA, et al. Am J Clin Pathol. 2001 Jan;115(1):148-55. doi: 10.1309/N7RA-D6XN-9EQX-ABJ9. Am J Clin Pathol. 2001. PMID: 11190801
• Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.

  Douglas AD, Jefferis J, Sharma R, Parker R, Handa A, Chantler J. Douglas AD, et al. Angiology. 2009 Jun-Jul;60(3):358-61. doi: 10.1177/0003319709332958. Epub 2009 Apr 26. Angiology. 2009. PMID: 19398428
• Limits of APTT for monitoring heparin.

  Vine DL. Vine DL. Kans Med. 1993 Jan;94(1):23-4. Kans Med. 1993. PMID: 8433544 No abstract available.
• [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].

  Lutze G, Presser HJ, Urbahn H. Lutze G, et al. Z Gesamte Inn Med. 1989 Apr 15;44(8):235-40. Z Gesamte Inn Med. 1989. PMID: 2662657 Review. German.
• [Monitoring of heparin in the treatment of deep venous thrombosis. An obsolete question?].

  Toulemonde F, Kher A. Toulemonde F, et al. Ann Cardiol Angeiol (Paris). 1995 Mar;44(3):151-9. Ann Cardiol Angeiol (Paris). 1995. PMID: 7793854 Review. French.